Clinician: Patients with immune system disorders are usually treated with a class of drugs that, unfortunately, increase the patient' s risk of developing osteoporosis, a bone-loss disease. So these patients take another drug that helps to preserve existing bone. Since a drug that enhances the growth of new bone cells has now become available, these patients should take this new drug in addition to the drug that helps to preserve existing bone.
To evaluate the clinician's argument, it would be most useful to know how large the class of drugs that increase the risk of developing osteoporosis is.